SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
== References == CDBaby.com BBC Radio 2 Interview (The Weekender with Matthew Wright - 3rd Nov 2006) The Times Newspaper (UK): Knowledge Section (Saturday 26 Nov 2006) Future Music Magazine interview (Nov 2005)
== Diagnosis == The diagnosis of HHV-6 infection is performed by both serologic and direct methods. The most prominent technique is the quantification of viral DNA in blood, other body fluids, and organs by means of real-time PCR.
cytosol Also hyaloplasm and groundplasm. The soluble aqueous phase of the cytoplasm, in which small particles such as ribosomes, proteins, nucleic acids, and many other molecules are suspended or dissolved, excluding larger structures and organelles such as mitochondria, chloroplasts, lysosomes, and the endoplasmic reticulum.
Sources: en.wikipedia.org
==== Monitoring ==== The therapeutic target range TSH level for patients on treatment ranges between 0.3 and 3.0 μIU/mL. For hypothyroid patients on thyroxine, measurement of TSH alone is generally considered sufficient. An increase in TSH above the normal range indicates under-replacement or poor compliance with therapy. A significant reduction in TSH suggests over-treatment. In both cases, a change in dose may be required. A low or low-normal TSH value may also signal pituitary disease in the absence of replacement. For hyperthyroid patients, both TSH and T4 are usually monitored. In pregnancy, TSH measurements do not seem to be a good marker for the well-known association of maternal thyroid hormone availability with offspring neurocognitive development. TSH distribution progressively shifts toward higher concentrations with age.
Although Calderón's strategy intended to end violence between rival cartels, critics argue that it worsened the conflict. By removing cartel leaders through arrests or killings, his administration created leadership vacuums that sparked internal power struggles and greater competition between cartels. Balance of power shifts meant that new cartels emerged as other groups weakened, for example, the fragmentation of La Familia Michoacana, which gave rise to the Knights Templar Cartel. Splintered cartels fought to exploit overlapping patches of smuggling routes and territories, and also sought to manipulate the system by leaking intelligence to Mexican authorities or the U.S. Drug Enforcement Administration (DEA) to turn law enforcement against their rivals, using knowledge from the groups they had broken away from. During Calderón's presidential term, the murder rate of Mexico increased dramatically. Annual homicides rose from more than 5,000 in 2008 to 9,600 in 2009 and over 15,000 in 2010. By the end of Calderón's presidency, his administration's statistics claimed that, during his six-year term, 50,000 drug-related homicides occurred. Outside sources claimed more than 120,000 murders happened in the same period as a result of Calderón's strategy. Some analysts, including U.S. Ambassador in Mexico Carlos Pascual, argued that this increase was a direct result of Calderón's military measures.
==== Monazite age mapping ==== Estimated ages are calculated across the compositional map by analysing the concentration of Th, Pb and U by the total-Pb dating method. The result is then used to generate an age map which approximately identifies all the age domains.
Sources: en.wikipedia.org
== Odor characteristics == The odour of the mixed isomers is perceived as "fatty, green, waxy, cucumber, melon". The odour of the (Z)-isomer is "orris, fatty, waxy, cucumber" whilst that of the (E)-isomer is "fatty, green, cucumber, aldehydic". Its odor has been associated with human body odor alterations during aging.
=== United States === Since a 1972 law, government insurance (Medicare) covers the cost of dialysis and transplants for citizens of any age with end stage renal disease. By 2014, more than 460,000 Americans were undergoing treatment, the costs of which amount to six percent of the entire Medicare budget. Kidney disease is the ninth leading cause of death, and the U.S. has one of the highest mortality rates for dialysis care in the industrialized world. The rate of patients getting kidney transplants has been lower than expected. These outcomes have been blamed on a new for-profit dialysis industry responding to government payment policies. A 1999 study concluded that "patients treated in for-profit dialysis facilities have higher mortality rates and are less likely to be placed on the waiting list for a renal transplant than are patients who are treated in not-for-profit facilities", possibly because transplantation removes a constant stream of revenue from the facility. The insurance industry has complained about kickbacks and problematic relationships between charities and providers.
The 8th district includes most of the northern and northwestern exurbs of Houston, including Conroe, part of Huntsville, Willis, Magnolia, Brookshire and Hempstead, along with parts of west Houston including Briar Forest, the western end of the Energy Corridor and most of the Bear Creek and Addicks areas in west Harris County. The incumbent is Republican Morgan Luttrell, who was elected with 68.2% of the vote in 2024. Luttrell is not seeking reelection in the heavily Republican district, which gave Donald Trump 63.2% and Ted Cruz 60.1% of the vote in 2024 and is a plurality White district with a 31.3% Hispanic voting age population.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.